Abstract
High-risk human papillomaviruses are the causative agents of cervical and other anogenital cancers. In these cancers, two viral oncogenes, E6 and E7, are expressed. E6 is best known for its ability to inactivate the tumor suppressor p53, which is thought to arise through ubiquitin-mediated degradation of p53 and involve a ternary complex between E6, p53 and the E3 ligase, E6AP. In mice transgenic for wild-type HPV16 E6, its expression leads to epithelial hyperplasia and an abrogation of normal cellular responses to DNA damage. Whereas only the latter phenotype is dependent upon E6's inactivation of p53, both are reduced in transgenic mice expressing an E6 mutant severely reduced in its binding to E6AP and other cellular proteins that bind E6 through a shared α-helix motif. Here, we investigated whether E6AP is required for the induction of the above phenotypes through the use of both E6AP-mutant and E6AP-null mice. E6, in the absence of E6AP retains an ability to induce epithelial hyperplasia, abrogate DNA damage responses and inhibit the induction of p53 protein following exposure to ionizing radiation. We conclude that E6 is able to induce both p53-dependent and p53-independent phenotypes through E6AP-independent pathways in the mouse.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Arbeit JM, Howley PM, Hanahan D . (1996). Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci USA 93: 2930–2935.
Band V, De Caprio JA, Delmolino L, Kulesa V, Sager R . (1991). Loss of p53 protein in human papillomavirus type 16 E6-immortalized human mammary epithelial cells. J Virol 65: 6671–6676.
Chellappan S, Kraus VB, Kroger B, Munger K, Howley PM, Phelps WC et al. (1992). Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc Natl Acad Sci USA 89: 4549–4553.
Cooper B, Schneider S, Bohl J, Jiang Y, Beaudet A, Vande Pol S . (2003). Requirement of E6AP and the features of human papillomavirus E6 necessary to support degradation of p53. Virology 306: 87–99.
Dyson N, Howley PM, Munger K, Harlow E . (1989). The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243: 934–937.
Fei P, El-Deiry WS . (2003). P53 and radiation responses. Oncogene 22: 5774–5783.
Gao Q, Kumar A, Singh L, Huibregtse JM, Beaudenon S, Srinivasan S et al. (2002). Human papillomavirus E6-induced degradation of E6TP1 is mediated by E6AP ubiquitin ligase. Cancer Res 62: 3315–3321.
Gewin L, Galloway DA . (2001). E box-dependent activation of telomerase by human papillomavirus type 16 E6 does not require induction of c-myc. J Virol 75: 7198–7201.
Gillison ML, Shah KV . (2001). Human papillomavirus-associated head and neck squamous cell carcinoma: mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers. Curr Opin Oncol 13: 183–188.
Grm HS, Banks L . (2004). Degradation of hDlg and MAGIs by human papillomavirus E6 is E6-AP-independent. J Gen Virol 85: 2815–2819.
Gross-Mesilaty S, Reinstein E, Bercovich B, Tobias KE, Schwartz AL, Kahana C et al. (1998). Basal and human papillomavirus E6 oncoprotein-induced degradation of Myc proteins by the ubiquitin pathway. Proc Natl Acad Sci USA 95: 8058–8063.
Hengstermann A, D'Silva M A, Kuballa P, Butz K, Hoppe-Seyler F, Scheffner M . (2005). Growth suppression induced by downregulation of E6-AP expression in human papillomavirus-positive cancer cell lines depends on p53. J Virol 79: 9296–9300.
Hengstermann A, Linares LK, Ciechanover A, Whitaker NJ, Scheffner M . (2001). Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc Natl Acad Sci USA 98: 1218–1223.
Herber R, Liem A, Pitot H, Lambert PF . (1996). Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene. J Virol 70: 1873–1881.
Hubbert NL, Sedman SA, Schiller JT . (1992). Human papillomavirus type 16 E6 increases the degradation rate of p53 in human keratinocytes. J Virol 66: 6237–6241.
Huibregtse JM, Scheffner M, Beaudenon S, Howley PM . (1995). A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc Natl Acad Sci USA 92: 5249.
Huibregtse JM, Scheffner M, Howley PM . (1991). A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J 10: 4129–4135.
Huibregtse JM, Scheffner M, Howley PM . (1993). Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol Cell Biol 13: 775–784.
Jiang YH, Armstrong D, Albrecht U, Atkins CM, Noebels JL, Eichele G et al. (1998). Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. Neuron 21: 799–811.
Kelley ML, Keiger KE, Lee CJ, Huibregtse JM . (2005). The global transcriptional effects of the human papillomavirus E6 protein in cervical carcinoma cell lines are mediated by the E6AP ubiquitin ligase. J Virol 79: 3737–3747.
Kishino T, Lalande M, Wagstaff J . (1997). UBE3A/E6-AP mutations cause Angelman syndrome. Nat Genet 15: 70–73.
Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB . (1992). Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89: 7491–7495.
Kuhne C, Banks L . (1998). E3-ubiquitin ligase/E6-AP links multicopy maintenance protein 7 to the ubiquitination pathway by a novel motif, the L2G box. J Biol Chem 273: 34302–34309.
Kumar A, Zhao Y, Meng G, Zeng M, Srinivasan S, Delmolino LM et al. (2002). Human papillomavirus oncoprotein E6 inactivates the transcriptional coactivator human ADA3. Mol Cell Biol 22: 5801–5812.
Lee C, Laimins LA . (2004). Role of the PDZ domain-binding motif of the oncoprotein E6 in the pathogenesis of human papillomavirus type 31. J Virol 78: 12366–12377.
Liu X, Yuan H, Fu B, Disbrow GL, Apolinario T, Tomaic V et al. (2005). The E6-AP ubiquitin ligase is required for transactivation of the hTERT promoter by the human papillomavirus E6 oncoprotein. J Biol Chem 280: 10807–10816.
Massimi P, Gammoh N, Thomas M, Banks L . (2004). HPV E6 specifically targets different cellular pools of its PDZ domain-containing tumour suppressor substrates for proteasome-mediated degradation. Oncogene 23: 8033–8039.
Matsumoto Y, Nakagawa S, Yano T, Takizawa S, Nagasaka K, Nakagawa K et al. (2006). Involvement of a cellular ubiquitin-protein ligase E6AP in the ubiquitin-mediated degradation of extensive substrates of high-risk human papillomavirus E6. J Med Virol 78: 501–507.
Matsuura T, Sutcliffe JS, Fang P, Galjaard RJ, Jiang YH, Benton CS et al. (1997). De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. Nat Genet 15: 74–77.
Miura K, Kishino T, Li E, Webber H, Dikkes P, Holmes GL et al. (2002). Neurobehavioral and electroencephalographic abnormalities in Ube3a maternal-deficient mice. Neurobiol Dis 9: 149–159.
Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R . (1989). The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 63: 4417–4421.
Nakagawa S, Huibregtse JM . (2000). Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Mol Cell Biol 20: 8244–8253.
Nakao M, Sutcliffe JS, Durtschi B, Mutirangura A, Ledbetter DH, Beaudet AL . (1994). Imprinting analysis of three genes in the Prader–Willi/Angelman region: SNRPN, E6-associated protein, and PAR-2 (D15S225E). Hum Mol Genet 3: 309–315.
Nguyen M, Song S, Liem A, Androphy E, Liu Y, Lambert PF . (2002). A mutant of human papillomavirus type 16 E6 deficient in binding alpha-helix partners displays reduced oncogenic potential in vivo. J Virol 76: 13039–13048.
Nguyen ML, Nguyen MM, Lee D, Griep AE, Lambert PF . (2003a). The PDZ ligand domain of the human papillomavirus type 16 E6 protein is required for E6's induction of epithelial hyperplasia in vivo. J Virol 77: 6957–6964.
Nguyen MM, Nguyen ML, Caruana G, Bernstein A, Lambert PF, Griep AE . (2003b). Requirement of PDZ-containing proteins for cell cycle regulation and differentiation in the mouse lens epithelium. Mol Cell Biol 23: 8970–8981.
Nomine Y, Masson M, Charbonnier S, Zanier K, Ristriani T, Deryckere F et al. (2006). Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis. Mol Cell 21: 665–678.
Pan H, Griep AE . (1994). Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: implications for tumor suppressor gene function in development. Genes Dev 8: 1285–1299.
Patel D, Huang SM, Baglia LA, McCance DJ . (1999). The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J 18: 5061–5072.
Pim D, Thomas M, Javier R, Gardiol D, Banks L . (2000). HPV E6 targeted degradation of the discs large protein: evidence for the involvement of a novel ubiquitin ligase. Oncogene 19: 719–725.
Riley RR, Duensing S, Brake T, Munger K, Lambert PF, Arbeit JM . (2003). Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res 63: 4862–4871.
Salvat C, Wang G, Dastur A, Lyon N, Huibregtse JM . (2004). The -4 phenylalanine is required for substrate ubiquitination catalyzed by HECT ubiquitin ligases. J Biol Chem 279: 18935–18943.
Scheffner M, Huibregtse JM, Vierstra RD, Howley PM . (1993). The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75: 495–505.
Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM . (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129–1136.
Simonson SJ, Difilippantonio MJ, Lambert PF . (2005). Two distinct activities contribute to human papillomavirus 16 E6's oncogenic potential. Cancer Res 65: 8266–8273.
Song S, Gulliver GA, Lambert PF . (1998). Human papillomavirus type 16 E6 and E7 oncogenes abrogate radiation-induced DNA damage responses in vivo through p53-dependent and p53-independent pathways. Proc Natl Acad Sci USA 95: 2290–2295.
Song S, Liem A, Miller JA, Lambert PF . (2000). Human papillomavirus types 16 E6 and E7 contribute differently to carcinogenesis. Virology 267: 141–150.
Song S, Pitot HC, Lambert PF . (1999). The human papillomavirus type 16 E6 gene alone is sufficient to induce carcinomas in transgenic animals. J Virol 73: 5887–5893.
Taketo M, Schroeder AC, Mobraaten LE, Gunning KB, Hanten G, Fox RR et al. (1991). FVB/N: an inbred mouse strain preferable for transgenic analyses. Proc Natl Acad Sci USA 88: 2065–2069.
Talis AL, Huibregtse JM, Howley PM . (1998). The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. J Biol Chem 273: 6439–6445.
Thomas MC, Chiang CM . (2005). E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation. Mol Cell 17: 251–264.
Traidej M, Chen L, Yu D, Agrawal S, Chen J . (2000). The roles of E6-AP and MDM2 in p53 regulation in human papillomavirus-positive cervical cancer cells. Antisense Nucleic Acid Drug Dev 10: 17–27.
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al. (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12–19.
Werness BA, Levine AJ, Howley PM . (1990). Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248: 76–79.
zur Hausen H . (1996). Papillomavirus infections – a major cause of human cancers. Biochim Biophys Acta 1288: F55–F78.
Acknowledgements
We thank Drs Drinkwater and Sugden for critical reading of the paper, members of the Lambert lab for helpful discussions and Lawrence Banks for the communication of unpublished observations. This study was supported by Grants CA098428, CA022443, CA014520 and CA009135 from the NIH.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shai, A., Nguyen, M., Wagstaff, J. et al. HPV16 E6 confers p53-dependent and p53-independent phenotypes in the epidermis of mice deficient for E6AP. Oncogene 26, 3321–3328 (2007). https://doi.org/10.1038/sj.onc.1210130
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210130
Keywords
This article is cited by
-
HPV-16 impairs the subcellular distribution and levels of expression of protein phosphatase 1γ in cervical malignancy
BMC Cancer (2015)
-
Ubiquitination involved enzymes and cancer
Medical Oncology (2014)
-
Large-scale analysis of protein expression changes in human keratinocytes immortalized by human papilloma virus type 16 E6 and E7 oncogenes
Proteome Science (2009)
-
Comparison of p53 and the PDZ domain containing protein MAGI-3 regulation by the E6 protein from high-risk human papillomaviruses
Virology Journal (2008)